Original Article | Published:

Effect of IL-1β, TNF-α and IGF-1 on trans-endothelial passage of synthetic vectors through an in vitro vascular endothelial barrier of striated muscle

Gene Therapy volume 24, pages 416424 (2017) | Download Citation

Abstract

When administrated in the blood circulation, plasmid DNA (pDNA) complexed with synthetic vectors must pass through a vascular endothelium to transfect underlying tissues. Under inflammatory condition, cytokines can modify the endothelium integrity. Here, the trans-endothelial passage (TEP) of DNA complexes including polyplexes, lipoplexes and lipopolyplexes was investigated in the presence of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) or insulin-like growth factor-1 (IGF-1). The experiments were performed by using an in vitro model comprising a monolayer of mouse cardiac endothelial cells (MCEC) seeded on a trans-well insert and the transfection of C2C12 myoblasts cultured on the lower chamber as read out of TEP. We report that polyplexes made with a histidinylated derivative of lPEI (His-lPEI) exhibit the highest capacity (10.5 μg cm2 h versus 0.324 μg cm2 h) to cross TNF-α-induced inflamed endothelium model, but this positive effect is counterbalanced by the presence of IL-1β. His-lPEI polyplex TEP is also increased in the presence of IGF-1 (2.58 μg cm2 h). TEP of lipid-based DNA complexes including lipoplexes and lipopolyplexes was lowest compared with polymer-based DNA complexes. Overall, the results indicate that under inflammation, His-lPEI polyplexes have a good profile to cross a vascular endothelium of striated muscle with low cytotoxicity and high transfection efficiency of C2C12 myoblasts. These data provide insights concerning the endothelial passage of vectors in inflammatory conditions and can serve as a basis towards in vivo studies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , . Nonviral approach for targeted nucleic acid delivery. Curr Med Chem 2012; 19: 197–208.

  2. 2.

    , . Nonviral vectors for gene delivery. Chem Rev 2009; 109: 259–302.

  3. 3.

    , . To be targeted: is the magic bullet concept a viable option for synthetic nucleic acid therapeutics? Hum Gene Ther 2011; 22: 799–807.

  4. 4.

    , , . Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci 2010; 40: 159–170.

  5. 5.

    , , . Ability of plasmid DNA complexed with histidinylated lPEI and lPEI to cross in vitro lung and muscle vascular endothelial barriers. Gene 2013; 525: 182–190.

  6. 6.

    , , , , . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271–284.

  7. 7.

    . To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release 2016; 244: 108–121.

  8. 8.

    , , , . Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug Chem 2016; 27: 2225–2238.

  9. 9.

    , . Scanning for therapeutic targets within the cytokine network of idiopathic inflammatory myopathies. Int J Mol Sci 2015; 16: 18683–18713.

  10. 10.

    , . Inflammation induced loss of skeletal muscle. Bone 2015; 80: 131–142.

  11. 11.

    , , , . The mechanisms of cachexia underlying muscle dysfunction in COPD. J Appl Physiol 2013; 114: 1253–1262.

  12. 12.

    , , , , . Understanding the process of fibrosis in Duchenne muscular dystrophy. Biomed Res Int 2014; 2014: 965631.

  13. 13.

    , , , , , et al. Fibrogenic cell plasticity blunts tissue regeneration and aggravates muscular dystrophy. Stem Cell Rep 2015; 4: 1046–1060.

  14. 14.

    , . Cytokines and chemokines as regulators of skeletal muscle inflammation: presenting the case of Duchenne muscular dystrophy. Mediators Inflamm 2013; 2013: 540370.

  15. 15.

    , , , , . Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in Duchenne muscular dystrophy. Am J Phys Med Rehabil 2009; 88: 502–522.

  16. 16.

    , , , , . Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention. PM R 2009; 1: 755–768.

  17. 17.

    , , , , , et al. Persistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. Neuromuscul Disord 2003; 13: 223–235.

  18. 18.

    , , , , , et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 2002; 11: 263–272.

  19. 19.

    , , . Cytokines and growth factors in Duchene muscular dystrophy patients. Egypt J Med Hum Genet 2009; 9: 181–188.

  20. 20.

    , , . Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995; 63: 9–16.

  21. 21.

    , , , , . Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81: 1162–1172.

  22. 22.

    , , , . The role of the IGF-I receptor in the growth and transformation of mammalian cells. Cell Prolif 1994; 27: 63–71.

  23. 23.

    , , , , . Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G1/S cell cycle progression via the activation of phosphatidylinositol 3'-kinase/Akt signaling pathway. J Biol Chem 2000; 275: 35942–35952.

  24. 24.

    , , . Anabolic agents for improving muscle regeneration and function after injury. Clin Exp Pharmacol Physiol 2008; 35: 852–858.

  25. 25.

    , , , , , et al. IL-1beta impairs insulin-like growth factor i-induced differentiation and downstream activation signals of the insulin-like growth factor i receptor in myoblasts. J Immunol 2004; 172: 7713–7720.

  26. 26.

    , , , , . Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle. Clin Exp Pharmacol Physiol 2008; 35: 846–851.

  27. 27.

    , , , , , et al. TNF alpha inhibits myogenic differentiation of C2C12 cells through NF-κB activation and impairment of IGF-1 signaling pathway. Biochem Biophys Res Commun 2015; 458: 790–795.

  28. 28.

    . Role of IGF-I in skeletal muscle mass maintenance. Trends Endocrinol Metab 2009; 20: 349–356.

  29. 29.

    , , , . The therapeutic potential of IGF-I in skeletal muscle repair. Trends Endocrinol Metab 2013; 24: 310–319.

  30. 30.

    , , , . Insulin and IGF-I induce pronounced hypertrophy of skeletal myofibers in tissue culture. Am J Physiol 1991; 260: C475–C484.

  31. 31.

    , , , , , et al. Lipophosphonate/lipophosphoramidates: a family of synthetic vectors efficient for gene delivery. Biochimie 2012; 94: 33–41.

  32. 32.

    , , , , , et al. Histidinylated linear PEI: a new efficient non-toxic polymer for gene transfer. Chem Commun 2011; 47: 12547–12549.

  33. 33.

    , , , , , et al. Gene transfer by chemical vectors, and endocytosis routes of polyplexes, lipoplexes and lipopolyplexes in a myoblast cell line. Biomaterials 2012; 33: 2980–2990.

  34. 34.

    , , , , , et al. Synthesis and transfection activity of new cationic phosphoramidate lipids: high efficiency of an imidazolium derivative. Chembiochem 2008; 9: 1462–1471.

  35. 35.

    , , , , , et al. Paromomycin and neomycin B derived cationic lipids: synthesis and transfection studies. J Control Release 2012; 158: 461–469.

  36. 36.

    , , . Up-regulation of the tight-junction protein ZO-1 by substance P and IGF-1 in A431 cells. Cell Biochem Funct 2009; 27: 388–394.

  37. 37.

    , , , , , et al. Maintenance of paracellular barrier function by insulin-like growth factor-I in submandibular gland cells. Arch Oral Biol 2010; 55: 963–969.

  38. 38.

    , , , , , et al. Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. J Mol Cell Cardiol 2014; 74: 139–150.

  39. 39.

    , . Cytokine-endothelial interactions in inflammation, immunity, and vascular injury. J Am Soc Nephrol 1990; 1: 225–235.

  40. 40.

    , . Skeletal muscle cytokines: regulation by pathogen-associated molecules and catabolic hormones. Curr Opin Clin Nutr Metab Care 2005; 8: 255–263.

  41. 41.

    , . Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1173–R1187.

  42. 42.

    , , . Systemic inflammation in Duchenne Muscular Dystrophy: Association with muscle function and nutritional status. Biomed Res Int 2015; 2015: 891972.

  43. 43.

    , , , , , et al. Haemostatic abnormalities, cardiac involvement and serum tumor necrosis factor levels in X-linked dystrophic patients. Thromb Haemost 1999; 81: 543–546.

  44. 44.

    . [Clinical significance of measurement of circulating tumor necrosis factor alpha]. Rinsho Byori 2001; 49: 829–833.

  45. 45.

    , , , . Phenotypic differences between mdx black mice and mdx albino mice. Comparison of cytokine levels in the blood. Bull Exp Biol Med 2013; 155: 376–379.

  46. 46.

    , , , , , et al. Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol 2006; 29: 328–335.

  47. 47.

    , , . Cachexia—induced cerebellar degeneration: involvement of serum TNF and MCP-1 in the course of experimental neoplastic disease. Acta Neurobiol Exp 2006; 66: 113–122.

  48. 48.

    , , , , , et al. Serum cytokine profiles in patients with prostate carcinoma. Exp Ther Med 2011; 2: 887–891.

  49. 49.

    , , , . TNF stimulation induces VHL overexpression and impairs angiogenic potential in skeletal muscle myocytes. Int J Mol Med 2014; 34: 228–236.

  50. 50.

    , , , . Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 2002; 283: E1279–E1290.

  51. 51.

    , , . Transient exposure of human myoblasts to tumor necrosis factor-alpha inhibits serum and insulin-like growth factor-I stimulated protein synthesis. Endocrinology 1997; 138: 4153–4159.

  52. 52.

    , . Tumor necrosis factor-alpha and basic fibroblast growth factor differentially inhibit the insulin-like growth factor-I induced expression of myogenin in C2C12 myoblasts. Exp Cell Res 1999; 249: 177–187.

  53. 53.

    , , , , , et al. Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies. Arthritis Rheumatol 2014; 66: 1022–1033.

  54. 54.

    , . Balancing protection and release of DNA: tools to address a bottleneck of non-viral gene delivery. J R Soc Interface 2010; 7 : S67–S82.

  55. 55.

    , , , , , et al. Brain-derived neurotrophic factor prevents the endothelial barrier dysfunction induced by interleukin-1beta and tumor necrosis factor-alpha. J Periodontal Res 2015; 50: 444–451.

  56. 56.

    , . Modulation of human endothelial cell permeability by combinations of the cytokines interleukin-1 alpha/beta, tumor necrosis factor-alpha and interferon-gamma. Immunopharmacology 1993; 25: 1–9.

  57. 57.

    , , , , . TNF-alpha signals through PKCzeta/NF-kappaB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes 2010; 59: 2872–2882.

  58. 58.

    , , , , , et al. Cytoskeletal rearrangement mediates human microvascular endothelial tight junction modulation by cytokines. Am J Physiol 1997; 273: H286–H294.

  59. 59.

    , , , , , . Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am J Physiol 1989; 257: L399–L410.

  60. 60.

    , , . Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci 2005; 108: 205–213.

  61. 61.

    , , , , , et al. Transport across a polarized monolayer of Caco-2 cells by transferrin receptor-mediated adenovirus transcytosis. Virology 2004; 325: 116–128.

  62. 62.

    , , , , , et al. Active and selective transcytosis of cell-free human immunodeficiency virus through a tight polarized monolayer of human endometrial cells. J Virol 2001; 75: 5370–5374.

  63. 63.

    , , , , , . Transfection efficiency and uptake process of polyplexes in human lung endothelial cells: a comparative study in non-polarized and polarized cells. J Gene Med 2005; 7: 729–738.

  64. 64.

    , , , , , et al. Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther 2007; 14: 604–612.

  65. 65.

    , , , , . The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther 2008; 15: 1193–1199.

  66. 66.

    , , , , , et al. An optimized extended DNA kappa B site that enhances plasmid DNA nuclear import and gene expression. J Gene Med 2009; 11: 401–411.

  67. 67.

    , , , , . An E3-14.7K peptide that promotes microtubules-mediated transport of plasmid DNA increases polyplexes transfection efficiency. Small 2013; 9: 3845–3851.

  68. 68.

    , , , , , et al. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J Pharmacol Exp Ther 1999; 291: 1017–1022.

  69. 69.

    , , , , , et al. Transcytosis-targeting peptide: a conductor of liposomal nanoparticles through the endothelial cell barrier. Small 2015; 12: 1212–1221.

  70. 70.

    , , , , . Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release 2015; 203: 1–15.

  71. 71.

    . Adsorptive-mediated brain delivery systems. Curr Pharm Biotechnol 2012; 13: 2340–2348.

  72. 72.

    , , , , . Anti-Abeta-MAb and dually decorated nanoliposomes: effect of Abeta1-42 peptides on interaction with hCMEC/D3 cells. Eur J Pharm Biopharm 2012; 81: 49–56.

  73. 73.

    , , , , , et al. Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies. Pharm Res 2014; 31: 1275–1289.

  74. 74.

    , , , , , . Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol 1986; 124: 179–185.

  75. 75.

    , , . Cytokine regulation of interleukin 6 production by human endothelial cells. Cell Immunol 1989; 121: 372–382.

  76. 76.

    , , , , , et al. Increased levels of interleukin-6 exacerbate the dystrophic phenotype in mdx mice. Hum Mol Genet 2015; 24: 6041–6053.

  77. 77.

    , , , . Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-κB. FASEB J 2001; 15: 1169–1180.

  78. 78.

    , . Effect of tumor necrosis factor-alpha on skeletal muscle metabolism. Curr Opin Rheumatol 2001; 13: 483–487.

  79. 79.

    , , , , , et al. Effect of nuclear factor kappaB inhibition on serotype 9 adeno-associated viral (AAV9) minidystrophin gene transfer to the mdx mouse. Mol Med 2012; 18: 466–476.

  80. 80.

    , . Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate. J Immunol 1987; 139: 1161–1167.

  81. 81.

    , , , , . Insulin and IGF1 receptors in human cardiac microvascular endothelial cells: metabolic, mitogenic and anti-inflammatory effects. J Endocrinol 2012; 215: 89–96.

  82. 82.

    , , , , , et al. Self-assembled lamellar complexes of siRNA with lipidic aminoglycoside derivatives promote efficient siRNA delivery and interference. Proc Natl Acad Sci USA 2007; 104: 16534–16539.

  83. 83.

    , , , , , et al. mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Ther 2007; 14: 802–814.

Download references

Acknowledgements

We thank David Gosset (Cytometry and Cellular Imaging P@CYFIC platform CBM) for his technical assistance. This work was supported by grants from ‘Association Française contre les Myopathies’ (Strategic project 2009, no 15628AFM (AFM, Evry, France) and Vaincre La Mucoviscidose (VLM, Paris, France).

Author information

Affiliations

  1. Centre de Biophysique Moléculaire, CNRS UPR4301, Inserm and University of Orléans, Orléans, France

    • J P Gomez
    • , C Gonçalves
    • , C Pichon
    •  & P Midoux

Authors

  1. Search for J P Gomez in:

  2. Search for C Gonçalves in:

  3. Search for C Pichon in:

  4. Search for P Midoux in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to P Midoux.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/gt.2017.40

Supplementary Information accompanies this paper on Gene Therapy website (http://www.nature.com/gt)